173 related articles for article (PubMed ID: 36817926)
21. Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity.
Pasoto SG; Halpern ASR; Guedes LKN; Ribeiro ACM; Yuki ENF; Saad CGS; da Silva CAA; de Vinci Kanda Kupa L; Villamarín LEB; de Oliveira Martins VA; Martins CCMF; Deveza GBH; Leon EP; Bueno C; Pedrosa TN; Santos REB; Soares R; Aikawa NE; Bonfa E
Clin Rheumatol; 2022 Jul; 41(7):2079-2089. PubMed ID: 35306594
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal profile of neutralizing and binding antibodies in vaccinated and convalescent COVID-19 cohorts by chemiluminescent immunoassays.
Dou X; Wang E; Jiang R; Li M; Xiong D; Sun B; Zhang X
Immun Inflamm Dis; 2022 Jun; 10(6):e612. PubMed ID: 35634960
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
24. SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines.
Di Giacomo AM; Giacobini G; Anichini G; Gandolfo C; D'alonzo V; Calabrò L; Lofiego MF; Cusi MG; Maio M
Eur J Cancer; 2022 Aug; 171():143-149. PubMed ID: 35717822
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults.
Yorsaeng R; Suntronwong N; Phowatthanasathian H; Assawakosri S; Kanokudom S; Thongmee T; Vichaiwattana P; Auphimai C; Wongsrisang L; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
Vaccine; 2022 Jan; 40(3):524-530. PubMed ID: 34893344
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Immunogenicity by Pseudovirus Neutralization Assays for SARS-CoV-2 Variants after Primary and Booster Immunization.
Xie H; Wen X; Li J; Chen W; Chen M; Zhang L; Lv M; Zhou S; Bai S; Zhao W; Wang J; Wu J
Int J Infect Dis; 2022 Apr; 117():97-102. PubMed ID: 35123028
[TBL] [Abstract][Full Text] [Related]
27. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
[TBL] [Abstract][Full Text] [Related]
28. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
Shinjo SK; de Souza FHC; Borges IBP; Dos Santos AM; Miossi R; Misse RG; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Kupa LVK; Ceneviva C; Seraphim JC; Pedrosa TN; Vendramini MBG; Silva CA; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Aug; 61(8):3351-3361. PubMed ID: 34664616
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study.
Monin L; Laing AG; Muñoz-Ruiz M; McKenzie DR; Del Molino Del Barrio I; Alaguthurai T; Domingo-Vila C; Hayday TS; Graham C; Seow J; Abdul-Jawad S; Kamdar S; Harvey-Jones E; Graham R; Cooper J; Khan M; Vidler J; Kakkassery H; Sinha S; Davis R; Dupont L; Francos Quijorna I; O'Brien-Gore C; Lee PL; Eum J; Conde Poole M; Joseph M; Davies D; Wu Y; Swampillai A; North BV; Montes A; Harries M; Rigg A; Spicer J; Malim MH; Fields P; Patten P; Di Rosa F; Papa S; Tree T; Doores KJ; Hayday AC; Irshad S
Lancet Oncol; 2021 Jun; 22(6):765-778. PubMed ID: 33930323
[TBL] [Abstract][Full Text] [Related]
30. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
[TBL] [Abstract][Full Text] [Related]
31. Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies.
Gressens SB; Fourati S; Le Bouter A; Le Bras F; Dupuis J; Hammoud M; El Gnaoui T; Gounot R; Roulin L; Belhadj K; Haioun C; Gallien S; Melica G; Lemonnier F
Clin Microbiol Infect; 2022 Jun; 28(6):885.e7-885.e11. PubMed ID: 35259530
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
33. Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer.
Han Y; Yang J; He D; Feng Y; Liu X; Min Y; Fan S; Yin G; Hu D
Front Immunol; 2022; 13():855311. PubMed ID: 35634276
[TBL] [Abstract][Full Text] [Related]
34. Antibody response to SARS-CoV-2 WT and Omicron BA.4/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization.
Chen C; Dai L; Zheng C; Li H; Li X; Yang M; Gao R; Yao J; Zhang Z; Shi Y; Han X
J Hematol Oncol; 2023 May; 16(1):47. PubMed ID: 37138279
[TBL] [Abstract][Full Text] [Related]
35. Antibody response to inactivated COVID-19 vaccine in patients with type 2 diabetes mellitus after the booster immunization.
Li H; Wang Y; Li X; Wang S; Feng X; Xiao X; Li Y
J Diabetes; 2023 Nov; 15(11):931-943. PubMed ID: 37518861
[TBL] [Abstract][Full Text] [Related]
36. Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases.
Chen Z; Wang Y; He T; Li H; Ao L; Pan Q; Zhou Y; Zhu Q; Xiang D; Zhang G; Ling N; Chen M; Hu P; Peng M; Cai D; Zhang D; Ren H
J Clin Transl Hepatol; 2024 Feb; 12(2):162-171. PubMed ID: 38343613
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity of BNT162b2 Vaccine Booster Dose in Patients With Inflammatory Bowel Disease Receiving Infliximab Combination Therapy: A Prospective Observational Study.
Shehab M; Alrashed F; Alfadhli A; Alsayegh A; Aldallal U; Alsayegh M; Cherian P; Alkhair I; Thanaraj TA; Channanath A; Dashti AA; Albanaw A; Ali H; Abu-Farha M; Abubaker J; Al-Mulla F
Front Med (Lausanne); 2022; 9():933996. PubMed ID: 35860742
[TBL] [Abstract][Full Text] [Related]
38. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
[TBL] [Abstract][Full Text] [Related]
39. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
40. Impaired antibody responses were observed in patients with type 2 diabetes mellitus after receiving the inactivated COVID-19 vaccines.
Xiang F; Long B; He J; Cheng F; Zhang S; Liu Q; Chen Z; Li H; Chen M; Peng M; Yin W; Liu D; Ren H
Virol J; 2023 Feb; 20(1):22. PubMed ID: 36750902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
